NCT01313117View on ClinicalTrials.gov

Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

January 31, 2014

Conditions
Peripheral Neuropathy
Interventions
DRUG

Alpha lipoic acid

The baseline dose is 100 mg three times daily for four months. Dose escalation will occur until a maximum tolerated dose is found.

Trial Locations (1)

60611

Northwestern Medical Faculty Foundation, Chicago

All Listed Sponsors
lead

Northwestern University

OTHER

NCT01313117 - Alpha-lipoic Acid in Patients at Risk for Paclitaxel Induced Neuropathy | Biotech Hunter | Biotech Hunter